A PHASE 2 STUDY EVALUATING THE EFFICACY AND SAFETY OF;SELINEXOR (KPT-330) IN PATIENTS WITH RECURRENT GLIOMAS - KING (KPT-330 in Gliomas) KCP-330-004

Karyopharm Therapeutics, Inc.0 个研究点目标入组 30 人开始时间: 待定最近更新: 2024年4月23日

适应症

试验速览

阶段: 2 期
状态: 已完成
发起方: Karyopharm Therapeutics, Inc.
入组人数: 30

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: 18 至 99（—）

入选标准

•1. Confirmed diagnoses, as follows:;a. Arms A, B, C, and D: Pathologically confirmed GBM (including all histologic variants) at first diagnosis with radiographic evidence of recurrent disease after treatment with radiotherapy and temozolomide;;b. Arm E: Pathologically confirmed malignant gliomas other than GBM (WHO Grade 2 or Grade 3), with radiographic evidence of recurrent disease after treatment with radiotherapy and at least one line of systemic treatment;;c. Arm F: Pathologically confirmed GBM (including all histologic variants) or AG that is refractory to antiangiogenic treatment (defined as recurrence or progression of disease per RANO criteria during prior therapy with bevacizumab or other direct VEGF/VEGFR inhibitors) with radiographic evidence of recurrent disease after treatment with radiotherapy and temozolomide; ;2. Age >= 18 years; ;3. Karnofsky Performance Status (KPS) >= 60;;4. Patients enrolling in the medical arm (Arms B,C, D, E, and F) must be on a stable or decreasing dose of corticosteroids (or none) for at least 5 days prior to the baseline MRI;;5. Patients must have received prior treatment with radiation therapy and either temozolomide (Arms A, B, C, D, and F) or at least one line of systemic treatment (Arm E).;o Patients enrolling in the medical arm (Arms B, C, D, E, and F) must have an interval of at least 12 weeks from completion of radiation therapy and study unless there is histologic proof of active tumor from intervening resection.;6. Measurable disease (according to RANO guidelines, within 14 days of starting treatment). Measurable disease after surgery on Arm A is not required.;7. Written informed consent obtained prior to any screening procedures. Patients must be willing and able to comply with the protocol and aware of the investigational nature of this study.;8. Patients must have adequate bone marrow function and organ function within 2 weeks of study treatment as defined by the following laboratory criteria;;o Hematopoietic function: total white blood cell (WBC) count >= 3000/mm³, absolute neutrophil count (ANC) >= 1500/mm³, platelet count >= 125,000/mm³; hemoglobin >= 9g/dL.;o Hepatic function: bilirubin <= 2 times the upper limit of normal (ULN), ALT <= 2.5 times ULN, AST <= 2.5 times ULN; unless bilirubin elevation is related to Gilbert*s Syndrome for which bilirubin must be < 4 times ULN.;o Renal function: estimated creatinine clearance of >= 30 mL/min, calculated using the formula of Cockroft and Gault or other standard methods at the treating institution.;9. All female patients of childbearing potential must agree to use reliable methods of birth control during study treatment and for 3 months after the last dose of study drug and have a negative serum pregnancy test at screening. Reliable methods of contraception include intrauterine devices, hormonal contraceptives [contraceptive pills, implants, transdermal patches, hormonal vaginal devices or injections with prolonged release], abstinence or sterilization of the partner.;10. Fertile males must be willing to employ reliable methods of contraception during study treatment and for 3 months after the last dose of study drug.;11. Archived paraffin-embedded tissue: approximately 10 unstained slides (if less, contact Sponsor) or a tumor block must be available for confirmation of tumor diagnosis and correlative studies.;12. Patients in the Surgical Arm (Arm A) must be predicted pre-operatively to have sufficiently sized tumor to be resecte

排除标准

•1. Patients must not have significant medical illness that in the Investigator*s opinion cannot be adequately controlled with appropriate therapy or would compromise the patient*s ability to tolerate this therapy.;2. < 24 days from prior temozolomide, < 6 weeks from nitrosourea, < 4 weeks from other chemotherapy or investigational agents prior to start of treatment within study. ;3. For Arm F only: < 6 weeks from prior bevacizumab or other direct VEGF/VEGFR inhibitor prior to start of treatment within the study For any question of the definition of a direct VEGF/VEGFR inhibitor, consult Sponsor.;4. Unstable cardiovascular function.;5. Known active hepatitis A, B, or C infection; or known to be positive for HCV RNA or HBsAg (HBV surface antigen); hepatitis testing is not required.;6. Known HIV infection; HIV testing is not required.;7. Markedly decreased visual acuity if attributed to other causes than GBM for Arms A, C, and D, malignant gliomas other than GBM (WHO Grade 2 or Grade 3) for Arm E, or GBM or AG that is refractory to antiangiogenic treatment for Arm F.;8. Active infection requiring parenteral systemic antibiotics.;9. Patients with coagulation problems and medically significant bleeding in the month prior to start of treatment (e.g., peptic ulcer, epistaxis, spontaneous bleeding). Prior history of DVT or PE is not exclusionary.;10. Patients who are pregnant or breast-feeding.;11. Other cancer (except non-melanoma skin cancer or carcinoma in-situ of the cervix), unless in complete remission and off all therapy for that disease for a minimum of 3 years.;12. Patients must not have significantly diseased or obstructed gastrointestinal tract, malabsorption, uncontrolled vomiting or diarrhea, or inability to swallow oral medications.;13. Dehydration of National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) grade >= 1.;14. Patients must not have serious psychiatric or medical conditions that could interfere with treatment.;15. History of organ allograft.;16. Concurrent therapy with approved or investigational anticancer therapeutics.;17. Arms A, B, C, and D, only: Prior treatment with bevacizumab or other direct VEGF/ VEGFR inhibitors. For any question of the definition of a direct VEGF/VEGFR inhibitor, consult Sponsor.;18. Arms C and D only: body surface area < 1.2 m2, to avoid a dose exceeding the maximum allowable dose of 70 mg/m2.;.

研究者

发起方

Karyopharm Therapeutics, Inc.

相似试验

进行中（未招募）

1 期

EUCTR2016-003579-22-ESRoche Farma S.A. (Soc.unipersonal)que realiza el ensayo en España y que actúa como representante de F.Hoffmann- La Roche120

进行中（未招募）

1 期

EUCTR2016-003579-22-DEF. Hoffmann-La Roche Ltd55

进行中（未招募）

1 期

EUCTR2016-003579-22-LVF. Hoffmann-La Roche Ltd120

进行中（未招募）

1 期

A Study Exploring the Safety and Efficacy of Atezolizumab Administered in Combination with Obinutuzumab or Rituximab Anti-CD20 Therapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma, Marginal Zone Lymphoma and Waldenstr¿m MacroglobulinemiaRelapsed/Refractory Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL) and Waldenstr¿m Macroglobulinemia (WM)MedDRA version: 21.1Level: LLTClassification code 10054698Term: Waldenstrom's macroglobulinemia refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10026800Term: Mantle cell lymphoma recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10026801Term: Mantle cell lymphoma refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10077534Term: Marginal zone lymphoma refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10077533Term: Marginal zone lymphoma recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10054697Term: Waldenstrom's macroglobulinemia recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA v

EUCTR2016-003579-22-ITF. HOFFMANN - LA ROCHE LTD.55

进行中（未招募）

1 期

A Study Exploring the Safety and Efficacy of Atezolizumab Administered in Combination with Obinutuzumab or Rituximab Anti-CD20 Therapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma, Marginal Zone Lymphoma and Waldenström MacroglobulinemiaRelapsed/Refractory Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL) and Waldenström Macroglobulinemia (WM)MedDRA version: 20.0Level: LLTClassification code 10054697Term: Waldenstrom's macroglobulinemia recurrentSystem Organ Class: 100000013195MedDRA version: 20.0Level: LLTClassification code 10054698Term: Waldenstrom's macroglobulinemia refractorySystem Organ Class: 100000013206MedDRA version: 20.0Level: PTClassification code 10077534Term: Marginal zone lymphoma refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10077533Term: Marginal zone lymphoma recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10026801Term: Mantle cell lymphoma refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10026800Term: Mantle cell lymphoma recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2016-003579-22-GRF. Hoffmann-La Roche Ltd120